相关临床试验
21
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
4.8%
已完成
15
71.4%
终止
4
19.1%
撤回
1
4.8%
暂无批准数据
- Trogenix has appointed Atif Abbas, MD as Chief Medical Officer, bringing over 25 years of oncology drug development experience including successful IND submissions for immunotherapy compounds and regulatory approvals. - Carolyn Edwards, PhD joins as Vice President of R&D with over 15 years of drug development expertise, focusing on accelerating the company's immuno-oncology pipeline. - The appointments come as Trogenix prepares to advance its Odysseus platform into clinical trials, with the lead asset showing curative potential in preclinical glioblastoma studies. - The Odysseus platform utilizes AAV vectors and proprietary Synthetic Super-Enhancers to deliver a "Trojan horse" approach for potentially curative one-and-done treatments for aggressive cancers.
• Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies. • The fund has previously backed companies that achieved significant milestones, including FDA approvals for treatments targeting COPD, myelodysplastic syndrome, narcolepsy, and Prader-Willi Syndrome. • Several Vivo-backed companies have been acquired by pharmaceutical giants in billion-dollar deals, including RayzeBio (Bristol-Myers Squibb, $4.1B), Chinook Therapeutics (Novartis, $3.2B), and Sierra Oncology (GSK, $1.9B).
